TheraSonic appoints Geraldine Le Duc as chairwoman of its strategic committee
We’re proud to announce the appointment of Geraldine Le Duc as the new Chairwoman of Therasonic’s Strategic Committee. Geraldine brings ov…
Read moreEnabling drug delivery to the brain
At TheraSonic, we transform the treatment of brain diseases by enabling drug delivery to the brain using non-invasive focused ultrasound.
Discover our technology
- 0 + Years of research
- 0 + Scientific publications
- 0 Patents
Our mission
The blood-brain barrier (BBB) acts as a critical defense mechanism against harmful substances. However, this selectivity also impedes the delivery of therapeutic agents to the brain, a significant challenge in treating neurological disorders.
TheraSonic non-invasive device transiently disrupts the BBB using low-intensity focused ultrasound which facilitates the delivery of therapeutics at targeted locations in the brain.
Breakthrough in Brain Drug Delivery
Backed by over 15 years of academic research, this innovative technology enables non-invasive delivery of therapeutics to targeted areas of the brain.
-
Safety
Our real-time dosimetry solution ensures safe disruption of the blood-brain barrier using focused ultrasound for repeated treatments.
-
Accuracy
Based on state-of-the-art neuro-navigation solution, our system ensures precise targeting in the brain.
-
Multiple targets and volumes
Leveraging our medical robot technology, our platform enables treatment of multiple targets and large volume in a single session.
Our leadership team
Meet the talented individuals behind our groundbreaking medical device that aims to enhance drug delivery to the brain.
Our strategic committee
-
Geraldine Le Duc
Chairwoman of the strategic committee
-
Benoit Larrat, PhD
Founder, CEO
-
Nabil Osmani
Independent board member
-
Carsten Laue
M2care, Managing Partner
-
Christophe Javaud
Gustave Roussy Transfert, COO
Our milestones
-
2024
Company founded
TheraSonic is created as a spin-off from CEA and CNRS research.
-
2024
Pre-seed round
1M€ raised led by M2care with Gustave Roussy Transfert.
-
2024
Oncology Upward Investment
Selected to pitch at Matwin/Angels Sante event in Bordeaux.
-
2024
ISTU Taipei
Participated at the Annual International Symposium on Therapeutic Ultrasound.
-
2025
SNITEM Award
Won the Prix du Public at the SNITEM startup innovation day.
-
2025
VivaTech 2025
Featured by CEA at the French-German Tech Lab.
-
2025
Europe 1 Interview
CEO Benoit Larrat featured on "La France bouge".
-
2025
Strategic committee
Geraldine Le Duc appointed as chairwoman.
-
2026
Healthtech Trophy winner
Winner of the Trophée Jeune Entreprise HealthTech, awarded by France Biotech.
Our investors
TheraSonic has grown amongst leaders and innovators in their respective field.
Press & Awards
-
Interview "La France bouge" - Europe 1
-
Prix du Public - SNITEM Startup Day 2025
-
Winner - Trophée Jeune Entreprise HealthTech 2026
-
Featured at VivaTech 2025 - CEA Selection
Latest news
-
-
Therasonic to participate at the Annual Symposium on Therapeutic Ultrasound at Taipei, Taiwan
We are thrilled to announce that TheraSonic will be participating in the Annual International Symposium on Therapeutic Ultrasound organised by the Int…
Read more -
TheraSonic participates to Robotique Medicale Made In France Conference
TheraSonic will be present at the Robotique Medicale Made In France conference on October 9 in Montpellier. This not-to-be-missed event brings togethe…
Read more
